Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Giordano, A; Lin, N U; Tolaney, S M; Mayer, E L

Giordano, A; Lin, N U; Tolaney, S M; Mayer, E L.

Affiliation

Giordano A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Mayer EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA. Electronic address: erica_mayer@dfci.harvard.edu.

Ann Oncol ; 35(1): 10-14, 2024 Jan.

Article in En | MEDLINE | ID: mdl-37952893

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google